This is a working overview of regulatory schedule, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-15. Anything still debated is marked as such rather than presented as settled.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
=== Congenital cataract === In humans, a novel mutation of the COL4A1 gene coding for collagen type IV was found to be associated with autosomal dominant congenital cataract in a Chinese family. This mutation was not found in unaffected family members or in 200 unrelated controls. In this study, sequence analysis confirmed that the Gly782 amino acid residue was highly conserved. This report of a new mutation in the COL4A1 gene is the first report of a non-syndromic autosomal dominant congenital cataract that highlights an important role for collagen type IV in the physiological and optical properties of the lens.
=== Vascular type Ehlers-Danlos syndrome === Some patients with Vascular type Ehlers-Danlos, which is caused by mutations in COL3alpha1, are known to also have mutations in the COL1alpha1 gene. However the exact associations remain unknown.
== Development == Valve entered the VR space in the mid-2010s, demonstrating the Robot Repair VR demo at the 2015 Game Developers Conference. The following year, they partnered with HTC and released the HTC Vive, along with a series of "experiments" called The Lab. Plans to develop a new Half-Life game began after this, and Valve started a project named "The Prototype", helmed by Robin Walker. Concerned that other companies would limit the scope of VR technology, Walker felt that Valve had a duty as a game developer to get involved. Onboarding others in Hawaii opened up two more projects alongside the Index, those being the A.R.T.I. project and SimTrek. These plans ultimately fell through. Walker envisioned a controller that allowed for hand tracking, rather than just functioning as a remote control. The newly focused project developed a slimmed down headset and controllers, named the "Knuckles", that allowed for "believable" hands whilst in VR. Development kits for the Knuckles, codenamed "EV2", were showcased in 2018. Design elements, such as the large trackpad, were adapted from the HTC Vive controllers. These were later toned down, with a thumbstick implemented and a "track button", which is a tracking surface that sat between the stock and now centralised buttons. Hand sizes were considered so that the 5th to 95th percentiles would not have issues holding the Knuckles. Extra size customisations were included, as was a strap.
Sources: en.wikipedia.org
In August 1950, the Lao Prince Souphanouvong convened the first congress of the Pathet Lao, which was supported by Viet Minh and served as the vehicle for the communist challenge to French rule. On 13 August 1950, he was elected President of the Congress of the Pathet Lao, which met at the Việt Minh headquarters in Tuyen Quang, North Vietnam. In 1953, Pathet Lao fighters accompanied an invasion of Laos from Vietnam led by Viet Minh forces; they established a government at Viengxay in Houaphanh province, northeast Laos.
Protein crystallization is the process of formation of a regular array of individual protein molecules stabilized by crystal contacts. If the crystal is sufficiently ordered, it will diffract. Some proteins naturally form crystalline arrays, like aquaporin in the lens of the eye. In the process of protein crystallization, proteins are dissolved in an aqueous environment and sample solution until they reach the supersaturated state. Different methods are used to reach that state such as vapor diffusion, microbatch, microdialysis, and free-interface diffusion. Developing protein crystals is a difficult process influenced by many factors, including pH, temperature, ionic strength in the crystallization solution, and even gravity. Once formed, these crystals can be used in structural biology to study the molecular structure of the protein, particularly for various industrial or medical purposes.
== Effects on Animals == Calciseptine has been examined in vivo and in vitro in all kinds of animals, but mostly in rats. Calciseptine relaxes precontracted rat (thoracic) aorta and decreases blood pressure drastically. The decrease in blood pressure shows a combination of short- and long-lasting effects. The early, acute onset took five minutes, and the effect could last for 120 minutes or longer. In addition, calciseptine had only a small effect on the heart rhythm, changing it only slightly. Furthermore, it can also relax the trachea rings in the lungs. These effects can be explained by the relaxing activity of calciseptine on various smooth muscle cells. The inhibitory effect of calciseptine results in a decreased or total disappearance of electric activity in these cells. The total inhibitory effect depends on the tissue: the cardiovascular system is the most vulnerable, while neuronal cells are less vulnerable and skeletal muscle cells are completely resistant. This difference in tissue sensitivity is probably caused by slight differences in the L-type calcium channels in these tissues. These effects can occur at low subjected amounts of 0.1 till 1 μM calciseptine. In mouse myotube the Ca2+ currents show higher amplitude after incubation in calciseptine (1 μM). This effect of calciseptine on the Ca2+ current develops relatively fast. Calciseptine changes the reversal potential of the Ca2+ current in mouse myotubes. In adult frog skeletal muscle fibers calciseptine also causes an increased Ca2+ current.
Sources: en.wikipedia.org
== Adverse effects == Data from clinical trials submitted to regulatory authorities showed that rimonabant caused depressive disorders or mood alterations in up to 10% of subjects and suicidal ideation in around 1%, and in Europe it was contraindicated for people with any psychiatric disorder, including clinical depression. Data from a large, randomized, clinical trial (CRESCENDO) with > 9,000 patients receiving rimonabant treatment demonstrated a rate of psychiatric adverse events (anxiety, depression, depressed mood, or insomnia) of greater than 30%. Additionally, nausea and upper respiratory tract infections were very common adverse effects (occurring in more than 10% of people); common adverse effects (occurring in between 1% and 10% of people) included gastroenteritis, anxiety, irritability, insomnia and other sleep disorders, hot flushes, diarrhea, vomiting, dry or itchy skin, tendonitis, muscle cramps and spasms, fatigue, flu-like symptoms, and increased risk of falling. The FDA's advisory committee concurred with concerns raised by the review divisions. Based on human and on animal data, it appeared that the therapeutic window was narrow. EMA postmarketing surveillance data suggested that the risk of psychiatric disorders in people taking rimonabant was doubled.
== Management == D. dadantii is a member within the genus that is able to produce the pigment indigoidine. Rapid identification of this species utilizes this water-insoluble blue pigment appearing in the bacterial colonies as a chemotaxonomic trait. The presence of a soft rot may be an indication of a bacterial disease. However, many other organisms and plant disorders may appear as various soft rot or black lesions. Proper identification is important for treatment and control measures. Thus a differential media is used to culture Dickeya species and isolate or identify D. dadantii. Researchers at Fu Jen Catholic University in Taiwan developed a medium that differentiates D. dadantii from other species. This NGM medium contains nutrient agar (NA) and glycerol medium supplemented with MnCl2 :4H2O. To make this media, mix 23 g of nutrient agar, 10 ml glycerol (1% v/v), and 0.4 g MnCl2:4H2O (2 mM) to 1.0 liter of water. Note the pH of this media is 6.5 and it has a light brown base color. The proper temperature for culturing D. dadantii is 28 degrees Celsius. A positive result occurs when a bacterial streak produces a brownish blue color on the agar plate. Further isolation and extraction of the indigoidine pigment is possible using the methods described by Chatterejee and Brown. Currently there are no effective chemical controls for D. dadantii. The most important practices involve lowering the prevalence of disease by proper sanitation of materials, exclusion of infected materials, and avoiding environments conducive to disease.
=== Center of Excellence for Transgender Health (UCSF) === The Center of Excellence for Transgender Health at the University of California, San Francisco was established in 2009, dedicated to improving health equity for trans and gender nonconforming communities. The Center of Excellence for Transgender Health is a national advisory board composed of transgender leaders from across the United States, bringing expertise in the research of transgender health. Guidelines for Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People contains guidelines developed by The Center of Excellence for Transgender Health that are widely used clinical guidelines for transgender healthcare.
=== Generation and accumulation === Biomedical waste should be collected in containers that are leak-proof and sufficiently strong to prevent breakage during handling. Containers of biomedical waste are marked with a biohazard symbol. The container, marking, and labels are often red. Discarded sharps are usually collected in specialized boxes, often called needle boxes. Specialized equipment is required to meet OSHA 29 CFR 1910.1450 and EPA 40 CFR 264.173. standards of safety. Minimal recommended equipment include a fume hood and primary and secondary waste containers to capture potential overflow. Even beneath the fume hood, containers containing chemical contaminants should remain closed when not in use. An open funnel placed in the mouth of a waste container has been shown to allow significant evaporation of chemicals into the surrounding atmosphere, which is then inhaled by laboratory personnel, and contributes a primary component to the threat of completing the fire triangle. To protect the health and safety of laboratory staff as well as neighboring civilians and the environment, proper waste management equipment, such as the Burkle funnel in Europe and the ECO Funnel in the U.S., should be utilized in any department which deals with chemical waste. It is to be dumped after treatment. Operating Rooms ORs generate around one-third of waste in a hospital. This waste includes but is not limited to biohazards, plastic materials, pharmaceuticals, and linens. Moreover, ORs require large amounts of energy, causing a further negative environmental impact.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.